At the invitation of the University of Hong Kong, on the afternoon of July 29th, Dr. Wen Xiaoyan, Chairman of Zebra Pharmaceutical Company, gave a keynote speech titled "Zebrafish Models in Rare Disease Research and Drug Development" at the School of Chinese Medicine of the University of Hong Kong.

Dr. Wen Xiaoyan introduced to the teachers and students present how his team has used zebrafish for basic research in recent years, and collaborated with clinical doctors to establish zebrafish models, study rare disease genes, simulate human gene mutations, and explore treatment methods, thus promoting a technological revolution in biopharmaceutical research and development. He introduced that through zebrafish technology, scientists can manipulate the zebrafish genome and generate mutations required for disease modeling; With the establishment of high-throughput screening methods for zebrafish genetics and chemical genetics, international zebrafish research has entered a new era, which is expected to have a significant impact on promoting the development of precision medicine.

At the meeting, Dr. Wen Xiaoyan also revealed that Zebra Pharmaceutical Company has conducted effective chemogenetic screening for many major diseases such as hemorrhagic stroke, severe sepsis, and amyotrophic lateral sclerosis (ALS) in recent years, and has identified drug lead compounds. These drug pipelines will be further evaluated in clinical trials in the future.

At the seminar, Professor Feng Yibin, Dean of the School of Traditional Chinese Medicine at the University of Hong Kong, presented a souvenir to Dr. Wen Xiaoyan and had a small-scale exchange on the next steps of deep cooperation between the two sides. The two sides initially reached a willingness to cooperate.